Clinical efficacy of gamma-oryzanol combined with Femoston for perimenopausal syndrome

Table 1 Comparative analysis of baseline data

Factors	Control group (n = 59)	Observation group (n = 60)	χ2/t	P value
Age (years)	46.29 ± 6.47	45.97 ± 5.33	0.295	0.769
Disease course (months)	5.98 ± 0.94	6.17 ± 1.45	0.847	0.399
Body mass (kg)	60.83 ± 7.05	60.05 ± 7.71	0.576	0.566
Kupperman index (points)	28.51 ± 10.37	30.25 ± 11.89	0.850	0.397
Family medical history			1.245	0.265
With, n (%)	9 (15.25)	14 (23.33)
Without, n (%)	50 (84.75)	46 (76.67)